Eledon Pharmaceuticals (NASDAQ:ELDN) completed enrollment of its phase 2 BESTOW trial using its immunosuppressive drug tegoprubart for the prevention of organ rejection in patients who undergo ...

At the start of 2023, U.S. patent exclusivity expired for the blockbuster drug Humira, AbbVie's chief cash cow. During the 20 ...

In a remarkable medical breakthrough, doctors have successfully used stem cells to treat a debilitating eye condition that ...

O rgan and cell transplants are potentially life-saving treatments for a variety of medical conditions, but their success ...

Recent research confirms that the gut microbiome plays a causal role in various chronic diseases, including infections, ...

San Francisco–based Ossium Health has carried out three transplants for cancer patients using stem cells from deceased donors ...

Get ready for a hefty hike in your Medicare Part B premiums. Learn how the 2025 increase will affect your budget and what ...

In a study presented at the Summit on Stem Cell Derived Islets in Boston, researchers report on encouraging results using an experimental immunosuppressive drug in people with Type 1 diabetes.

Filippo Veglia, Ph.D., of Wistar’s Genome Regulation and Cell Signaling Program, discusses the most lethal form of brain cancer.

The "Scleroderma Diagnostics and Therapeutics - Global Strategic Business Report" report has been added to ResearchAndMarkets ...

Currently, the standard monthly Medicare Part B premium is $174.70. In 2025, it's rising to $185. That's an increase of ...